The Center for Pediatric Clinical Development

70% of the medicines given to children have only been studied in adults, and the majority of drugs used in children today are used off-label, without an adequate understanding of appropriate dose, safety, or efficacy.

Our industry is still guessing the clinical needs of children by settling for a fraction of what works in adults. We’re changing that.

At the Center for Pediatric Clinical Development, we have the unparalleled expertise and resources needed to run exceptional pediatric trials from start to finish. From our site network which allows us to consult with other global pediatric experts and easily recruit patients and our internal inter-departmental pediatric collaboration group to our extensive global pediatric regulatory understanding, we’ve tapped into the world’s best pediatric experts across the board to deliver pediatric-focused insights across all aspects of a clinical trial.

We help our clients save time and resources by determining the feasibility and effectiveness of pediatric studies at every phase of a program. Our global experience allows us to develop and execute country-specific, customized recruitment and retention initiatives to help study teams meet or exceed goals.

As a part of our commitment to lead the way in pediatric research, we established our Pediatric Site Network (PSN). PSN is a select group of internationally recognized pediatric centers and medical professionals from around the globe that share the common goal of bringing innovation to pediatric clinical design. Together, we are bringing new treatment options and access to novel medicines to the global pediatric patient population.

Improving pediatric patient engagement.

Age-appropriate and culturally sensitive health resources help patients feel informed and remain engaged. That’s why we partnered with Jumo, an award-winning provider of educational content, and their clinical trial resources, to provide engaging content that transforms the patient experience.

Guiding pediatric studies through today’s complex regulatory landscape.

Testing drugs in children presents considerable scientific, clinical, ethical, technical, and logistical challenges. Lack of incentives for companies to develop and test drugs, lack of necessary technology to monitor these patients and assay very small amounts of blood, and lack of suitable infrastructure have all discouraged the testing of drugs in pediatric populations. Today, several legislative initiatives are in place to provide incentives or to require study plans in the pediatric population.